Sustained lymphocyte decreases after treatment for early breast cancer
- Author(s)
- Dixon-Douglas, J; Virassamy, B; Clarke, K; Hun, M; Luen, SJ; Savas, P; van Geelen, CT; David, S; Francis, PA; Salgado, R; Michiels, S; Loi, S;
- Details
- Publication Year 2024-10-21,Volume 10,Issue #1,Page 94
- Journal Title
- NPJ Breast Cancer
- Publication Type
- Research article
- Abstract
- The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal study of full blood counts (FBC) of 200 patients receiving (neo)adjuvant chemotherapy for early breast cancer at a single institution. FBC results at four time points from pre-treatment to 12 months post-chemotherapy were analysed. Flow cytometry was performed for patients with matched pre- and post-chemotherapy peripheral blood mononuclear cell samples. A significant decrease in absolute lymphocyte count at 12 months post-chemotherapy was observed (p < 0.01), most pronounced in pre-menopausal patients (n = 73; p < 0.01), patients receiving dose-dense chemotherapy regimens (n = 60; p < 0.01) and patients receiving adjuvant radiotherapy (n = 147, p < 0.01). In pre-menopausal patients, significant changes in CD4(+) T cells subsets post-chemotherapy were observed. Further investigation, including long-term clinical outcomes, is needed to meaningfully improve long-term anti-tumour immunity.
- Publisher
- Springer Nature
- Department(s)
- Laboratory Research; Medical Oncology; Radiation Oncology
- Publisher's Version
- https://doi.org/10.1038/s41523-024-00698-4
- Open Access at Publisher's Site
https://doi.org/10.1038/s41523-024-00698-4- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-28 05:45:46
Last Modified: 2024-11-28 06:29:14